Literature DB >> 10613374

Relationship between tablet splitting and compliance, drug acquisition cost, and patient acceptance.

N G Fawell1, T L Cookson, S S Scranton.   

Abstract

As managed care pharmacy continues to grow and medication costs increase, pharmacy managers are continually looking for ways to reengineer distributive services to provide the most cost-effective care. In an effort to save money, the San Diego Veterans Affairs Healthcare System (SDVAHS) and other health systems have implemented tablet-splitting programs targeted at high-cost and widely prescribed medications. Despite this growing practice, published research examining the effects on compliance rates, patient acceptance, and actual cost savings is lacking. A recent computer-assisted literature search revealed only one study of tablet splitting that addressed patient compliance and acceptance. In that study, patients taking lovastatin and using a tablet splitter were mailed a questionnaire to assess their impressions of tablet splitting. A majority of the patients found tablet splitters easy to use and reported that compliance was not hindered. However, compliance was subjectively evaluated through patients' responses to questions; actual tablet counts were not performed. Furthermore, actual cost savings (if any) were not determined.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10613374     DOI: 10.1093/ajhp/56.24.2542

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  14 in total

1.  Use of a data warehouse to monitor simvastatin tablet splitting.

Authors:  Nicholas A Coblio; Kim A Mowrey; Dana Loos; V Ford; James A Haley
Journal:  AMIA Annu Symp Proc       Date:  2003

2.  The frequency of inappropriate tablet splitting in primary care.

Authors:  R Quinzler; C Gasse; A Schneider; P Kaufmann-Kolle; J Szecsenyi; W E Haefeli
Journal:  Eur J Clin Pharmacol       Date:  2006-10-06       Impact factor: 2.953

3.  Time series evaluation of an intervention to increase statin tablet splitting by general practitioners.

Authors:  Jennifer M Polinski; Sebastian Schneeweiss; Malcolm Maclure; Blair Marshall; Samuel Ramsden; Colin Dormuth
Journal:  Clin Ther       Date:  2011-02       Impact factor: 3.393

4.  Weight and content uniformity of lorazepam half-tablets: A study of correlation of a low drug content product.

Authors:  Abdel Naser Zaid; Rowa' J Al-Ramahi; Abeer Abu Ghoush; Aiman Qaddumi; Yara Abu Zaaror
Journal:  Saudi Pharm J       Date:  2012-01-05       Impact factor: 4.330

5.  Prediction of the ease of subdivision of scored tablets from their physical parameters.

Authors:  Koos C van der Steen; Henderik W Frijlink; C Maarten A Schipper; Dirk M Barends
Journal:  AAPS PharmSciTech       Date:  2010-01-15       Impact factor: 3.246

6.  Tablet Splitting of Antiepileptic Drugs in Pediatric Epilepsy: Potential Effect on Plasma Drug Concentrations.

Authors:  Ravi Prasad Nidanapu; Sundaram Rajan; Subramanian Mahadevan; Batmanabane Gitanjali
Journal:  Paediatr Drugs       Date:  2016-12       Impact factor: 3.022

7.  Potential savings from splitting newer antidepressant medications.

Authors:  Carl I Cohen; Sara I Cohen
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

8.  The practice of splitting tablets: cost and therapeutic aspects.

Authors:  John Bachynsky; Cheryl Wiens; Krystal Melnychuk
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

9.  Opportunities to reduce medication regimen complexity: a retrospective analysis of patients discharged from a university hospital in Germany.

Authors:  Diana Witticke; Hanna M Seidling; Kristina Lohmann; Alexander F J Send; Walter E Haefeli
Journal:  Drug Saf       Date:  2013-01       Impact factor: 5.606

10.  Tablet splitting of a narrow therapeutic index drug: a case with levothyroxine sodium.

Authors:  Rakhi B Shah; Jarrod S Collier; Vilayat A Sayeed; Arthur Bryant; Muhammad J Habib; Mansoor A Khan
Journal:  AAPS PharmSciTech       Date:  2010-08-26       Impact factor: 3.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.